SCHEMBL5765356

SCHEMBL5765356

NCc1ccc2oc(Cc3ccccc3)nc2c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.61
TP53 P04637 4/20 0.61
LMNA P02545 3/20 0.61
MAPT P10636 4/20 0.56
POLB P06746 2/20 0.56
NPC1 O15118 5/20 0.54
RAB9A P51151 5/20 0.54
HSD17B10 Q99714 3/20 0.54
KDM4E B2RXH2 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
FAAH O00519 1/20 0.52
CHRNB2 P17787 1/20 0.49
CHRNA4 P43681 1/20 0.49
MEN1 O00255 1/20 0.48
ELANE P08246 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11338435 0.86 SMN1; SMN2 (0.62) SMN1; SMN2TP53LMNAMAPTPOLB
SCHEMBL5766871 0.85 LMNA (0.61) SMN1; SMN2TP53LMNAMAPTPOLB
SCHEMBL29349698 0.83 SMN1; SMN2 (0.76) SMN1; SMN2TP53LMNAMAPTPOLB
SCHEMBL11638476 0.81 GAA (0.71) SMN1; SMN2TP53LMNAMAPTPOLB
SCHEMBL5077598 0.80 LMNA (0.58) SMN1; SMN2TP53LMNAMAPTPOLB
SCHEMBL4650036 0.79 TP53 (0.89) SMN1; SMN2TP53LMNAMAPTPOLB
SCHEMBL7993840 0.77 GRK6 (0.50) SMN1; SMN2TP53LMNAMAPTPOLB
SCHEMBL10227852 0.77 SMN1; SMN2 (0.68) SMN1; SMN2TP53MAPTPOLBNPC1
SCHEMBL5767249 0.76 LMNA (0.50) SMN1; SMN2TP53LMNAMAPTPOLB
SCHEMBL2247603 0.74 RAB9A (0.61) SMN1; SMN2TP53LMNAMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615636-A1 BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS PFIZER INC. (US) 2006-01-18 EP disclosed
WO-2004089366-A1 BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS PFIZER JAPAN, INC. (JP) 2004-10-21 WO disclosed
US-20040204409-A1 Bicyclic compounds as NR2B receptor antagonists ANDO KAZUO (JP) 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204409-A1 Bicyclic compounds as NR2B receptor antagonists GRIN1, GRIN2B, GRIN2A SMN1; SMN2 1857/4885TP53 4833/4885LMNA 3923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.